Oct 20 (Reuters) - Prometic Life Sciences Inc PLI.TO -
* Prometic's PBI-4050 meets primary and secondary end points in metabolic syndrome and type 2 diabetes phase 2 clinical trial
* PBI-4050 has been well tolerated with no serious drug related adverse events
* Clinically and statistically significant reduction of glycated hemoglobin originally observed at 12 weeks is maintained at 24 weeks of treatment
* Placebo-Controlled clinical trial to commence this quarter Source text for Eikon: ID:nCNW4NtZPa Further company coverage: PLI.TO